Moderna beats quarterly revenue estimates on resilient sales of COVID shot

SelfRugger · 2026-03-16T17:02:02+00:00

Moderna reported fourth-quarter revenue exceeding estimates due to stronger than expected sales of its COVID-19 vaccine, with $678 million compared to a forecast of $626.1 million. The company aims for 10% revenue growth in 2026 amidst declining vaccine demand.

SelfRugger

2026-03-16 17:02:02

Abstract generation in progress

Moderna beats quarterly revenue estimates on resilient sales of COVID shot

FILE PHOTO: A sign marks the headquarters of the coronavirus disease (COVID-19) vaccine maker Moderna in Cambridge, Massachusetts, U.S., April 28, 2022. REUTERS/Brian Snyder/File Photo · Reuters

Reuters

Fri, February 13, 2026 at 9:12 PM GMT+9 1 min read

In this article:

MRNA

-0.99%

Feb 13 (Reuters) - Moderna reported fourth-quarter revenue above ‌Wall Street estimates on ‌Friday, banking on better-than-expected sales of its COVID-19 vaccine in the U.S.

The Cambridge, Massachusetts-based company has been struggling ‌financially as ⁠demand for COVID vaccines collapsed in the ⁠years following its pandemic windfall. It is working on newer products to plug the ‌revenue gap and prove the long-term viability of its mRNA technology.

The company reiterated its expectation of 10% ‌revenue growth in 2026.

The vaccine maker’s quarterly revenue came in ‌at $678 million, compared with analysts’ average estimate of $626.1 million, according to data compiled by ‌LSEG.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli)

條款及私隱政策

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.